A detailed history of Virtus ETF Advisers LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 2,786 shares of VRTX stock, worth $1.4 Million. This represents 0.67% of its overall portfolio holdings.

Number of Shares
2,786
Previous 2,657 4.86%
Holding current value
$1.4 Million
Previous $1.11 Million 17.57%
% of portfolio
0.67%
Previous 0.61%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$392.81 - $485.53 $50,672 - $62,633
129 Added 4.86%
2,786 $1.31 Million
Q1 2024

May 15, 2024

BUY
$407.69 - $446.08 $107,630 - $117,765
264 Added 11.03%
2,657 $1.11 Million
Q4 2023

Feb 15, 2024

SELL
$343.0 - $410.68 $192,766 - $230,802
-562 Reduced 19.02%
2,393 $973,000
Q3 2023

Nov 07, 2023

SELL
$338.18 - $362.46 $135,272 - $144,984
-400 Reduced 11.92%
2,955 $1.03 Million
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $149,978 - $167,861
-477 Reduced 12.45%
3,355 $1.18 Million
Q1 2023

May 15, 2023

BUY
$283.23 - $323.1 $82,419 - $94,022
291 Added 8.22%
3,832 $1.21 Million
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $55,723 - $62,688
195 Added 5.83%
3,541 $1.02 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $71,195 - $79,437
-260 Reduced 7.21%
3,346 $969,000
Q2 2022

Aug 12, 2022

BUY
$234.96 - $292.55 $429,506 - $534,781
1,828 Added 102.81%
3,606 $1.02 Million
Q4 2021

Feb 14, 2022

SELL
$177.01 - $223.45 $101,249 - $127,813
-572 Reduced 24.34%
1,778 $390,000
Q3 2021

Nov 15, 2021

SELL
$181.39 - $202.99 $38,636 - $43,236
-213 Reduced 8.31%
2,350 $426,000
Q2 2021

Aug 10, 2021

SELL
$187.49 - $221.1 $32,998 - $38,913
-176 Reduced 6.43%
2,563 $517,000
Q1 2021

May 17, 2021

BUY
$207.02 - $241.31 $14,698 - $17,133
71 Added 2.66%
2,739 $589,000
Q4 2020

Feb 12, 2021

BUY
$207.01 - $276.09 $101,848 - $135,836
492 Added 22.61%
2,668 $631,000
Q3 2020

Nov 13, 2020

SELL
$255.65 - $303.1 $766 - $909
-3 Reduced 0.14%
2,176 $592,000
Q2 2020

Aug 05, 2020

SELL
$225.48 - $295.8 $113,190 - $148,491
-502 Reduced 18.72%
2,179 $633,000
Q1 2020

May 14, 2020

SELL
$199.77 - $247.81 $45,347 - $56,252
-227 Reduced 7.81%
2,681 $638,000
Q4 2019

Feb 13, 2020

SELL
$166.71 - $223.91 $193,383 - $259,735
-1,160 Reduced 28.52%
2,908 $637,000
Q3 2019

Nov 12, 2019

SELL
$166.23 - $187.09 $114,366 - $128,717
-688 Reduced 14.47%
4,068 $689,000
Q2 2019

Aug 13, 2019

BUY
$164.61 - $190.37 $54,156 - $62,631
329 Added 7.43%
4,756 $872,000
Q1 2019

May 14, 2019

BUY
$163.73 - $194.7 $146,047 - $173,672
892 Added 25.23%
4,427 $814,000
Q4 2018

Feb 05, 2019

SELL
$151.91 - $192.21 $230,295 - $291,390
-1,516 Reduced 30.01%
3,535 $586,000
Q3 2018

Nov 14, 2018

BUY
$167.73 - $192.74 $57,028 - $65,531
340 Added 7.22%
5,051 $974,000
Q2 2018

Aug 10, 2018

SELL
$145.72 - $169.96 $236,503 - $275,845
-1,623 Reduced 25.62%
4,711 $801,000
Q1 2018

May 14, 2018

SELL
$151.6 - $177.13 $73,374 - $85,730
-484 Reduced 7.1%
6,334 $1.03 Million
Q4 2017

Feb 14, 2018

SELL
$137.28 - $155.55 $203,448 - $230,525
-1,482 Reduced 17.86%
6,818 $1.02 Million
Q2 2017

Aug 14, 2017

BUY
N/A
8,300
8,300 $1.07 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.